


PHARMACEUTICAL 2018

CTI BIOPHARMA CORP Rank 264 of 342







PHARMACEUTICAL 2018

CTI BIOPHARMA CORP Rank 264 of 342



The relative strengths and weaknesses of CTI BIOPHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI BIOPHARMA CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 27% points. The greatest weakness of CTI BIOPHARMA CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is -28%, being 73% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	46,924
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,258
Liabilities, Non-Current	19,044
Other Assets	5,597
Other Compr. Net Income	544
Other Expenses	364
Other Liabilities	494
Other Net Income	-1,312
Other Revenues	25,146
Property and Equipment	2,365
Research and Development	32,866
Selling, General and Administrative Expense	31,435

Output Variable	Value in 1000 USD
Assets	54,886
Liabilities	38,796
Expenses	64,665
Revenues	25,146
Stockholders Equity	16,090
Net Income	-40,831
Comprehensive Net Income	-40,559
Economic Capital Ratio	-28%

